DXCM vs STE
Dexcom and STERIS plc, both Healthcare
Dexcom is the larger company at $28B against $20B. On trailing earnings STE is the cheaper of the two at a P/E of 29.9 against 35.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year DXCM returned +16% against +7.9% for STE.
| Figure | DXCM | STE |
|---|---|---|
| Last close | $88.96 | $237 |
| Market cap | $28B | $20B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 35.3 | 29.9 |
| Dividend yield | n/a | 1.0% |
| 1-year return | +16% | +7.9% |
| 5-year return | -31% | +14% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Dexcom
Revenue of $1.3B in Q2 2026, net income $249M. Its largest reported line is United States, 81% of the disclosed total.
STERIS plc
Revenue of $1.6B in Q4 2026, net income $220M. Its largest reported line is Healthcare, 71% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.